Absence of human leukocyte antigen-B*57:01 amongst patients on antiretroviral therapy in Nigeria: Implications for use of abacavir | Zendy

Maxwell Akanbi | Zendy; OcheO Agbaji | Zendy; Ihedinachi Otoh | Zendy; PatriciaE Agaba | Zendy; Rolake Akinsola | Zendy; V.O. Okolie | Zendy; P. Ugoagwu | Zendy; AliyuA Babadoko | Zendy; Adewumi Adediran | Zendy; FinomoO Finomo | Zendy; JonahO Abah | Zendy; HarunaM Muktar | Zendy; Sulaimon Akanmu | Zendy

Open Access

Absence of human leukocyte antigen-B*57:01 amongst patients on antiretroviral therapy in Nigeria: Implications for use of abacavir

Author(s) -

Maxwell Akanbi,

OcheO Agbaji,

Ihedinachi Otoh,

PatriciaE Agaba,

Rolake Akinsola,

V.O. Okolie,

P. Ugoagwu,

AliyuA Babadoko,

Adewumi Adediran,

FinomoO Finomo,

JonahO Abah,

HarunaM Muktar,

Sulaimon Akanmu

Publication year - 2019

Publication title -

nigerian postgraduate medical journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.261

H-Index - 19

ISSN - 1117-1936

DOI - 10.4103/npmj.npmj_75_19

Subject(s) - abacavir , nigerians , medicine , human leukocyte antigen , hla b , group b , hla b antigens , immunology , human immunodeficiency virus (hiv) , viral load , antigen , antiretroviral therapy , political science , law

The presence of human leukocyte antigen (HLA) B*57:01 allele predicts hypersensitivity reaction (HSR) to abacavir (ABC), a nucleoside reverse-transcriptase inhibitor used for human immunodeficiency virus (HIV) treatment. However, the prevalence of this allele amongst Nigerians with HIV is yet to be established. We aimed to determine the prevalence of HLA-B*57:01 allele amongst Nigerians with HIV infection.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research